P3 laboratory concept boom, related equipment manufacturers or usher in new opportunities

Pharmaceutical Network Market AnalysisP3 laboratory construction is the current market investment hot spotRecently, the National Health and Health Commission and other three departments issued the "Public Health Prevention and Control Capacity Building Program", the program proposed five major construction tasks: strengthening the modernization of the disease prevention and control system;in strengthening the modernization of disease prevention and control systems, mentioned the need to achieve at least one laboratory in each province that has reached the level of biosecurity level III (P3) and at least one laboratory at the level of biosecurity level II (P2) in each prefecture-level cityat present, China has a P4 laboratory, more than 40 P3 laboratories, mainly concentrated in Beijing, Shanghai, Hubei, Guangdong and a small number of provinces and citiesIn addition, Kantai Bio, Hualan Bio, Kexing Zhongwei and other vaccine companies are in the P3 laboratory constructionWith the release of the programme, the subsequent domestic demand for P3/P4 laboratory construction will continue to increaseIt is reported that the Guangdong Science and Technology Department has led the formation of a P3 laboratory planning and construction plan, planning and construction of 25 to 30 P3 laboratories, hoping to solve the basic P3 laboratory needs within three years, in five years at least to build a P4 laboratorymarket organizations predict that this year, the national P3 laboratory, P2 laboratory increments of about 250 and 3000, respectivelyThere are also industry sources according to this estimate, this year's domestic biological laboratory construction may be more than expectedindustry believes that in this context, it is expected that P3 laboratory-related equipment including biosafety cabinets, ventilation systems, high-precision testing experimental equipment, such as the demand will continue to increase, related equipment manufacturers or usher in new opportunitiesthe author learned that, in fact, there are pharmaceutical machine enterprises have received orders and received a high degree of attention in the industryOn May 21, Kexing Zhongwei vaccine workshop construction project Xilin bottle filling line, packaging line procurement single source announcement disclosed that Chutian Technology to provide xilin bottle filling line, fully automatic packaging line, the project is expected to be 20 millionnot only, Chutian Technology on May 22 also said on the investor interactive platform, the company's wholly-owned subsidiary Sichuan Pharmaceutical Design Institute Co., Ltdhas P3 biosecurity laboratory design capabilities, to undertake the design of the 8th People's Hospital of Guangzhou High-level Biosecurity Laboratoryaffected by this, May 27 opened, Chutian Technology board rose and stopped, as of the 27th noon close, the share price of 10.11 yuan / share, this is its third consecutive rise and fall On May 22, May 25 and May 26, three consecutive trading days of closing price deviation value scored more than 20% in addition to Chutian, a number of listed companies have recently expressed on the interactive platform to undertake P3 laboratory-related business For example, on May 28, Changhong Meiling said on the interactive platform that the company's controlling subsidiary, Zhongke Meiling Cryogenic Technology Co., Ltd., does business with Huada Gene, but that sales account for a smaller proportion of CNPC's overall sales and will not have a significant impact on Ciccumeilg May 27, Xinhua Pharmaceuticals said on the interactive platform, subsidiary Shandong Xinhua Pharmaceutical Co., Ltd Pharmaceutical Chemical Design Co., Ltd has P2, P3 laboratory design qualifications Han Zhong seiko also said on the 27th interactive platform, the company's vacuum pumps are mainly used in semiconductors, photovoltaics, lithium batteries and other industries, can be used in P2, P3 laboratory the same day, Shangrong Medical said on the interactive platform, the company currently has a professional team engaged in P3 and below the design and construction of laboratories, some of the company's products can be used in P2/P3 laboratory However, the company does not yet have the professional ability to build P4 laboratory Yihua Health said on May 26 on the interactive platform, the company's wholly-owned subsidiary Zhongkang Logistics Group Co., Ltd holds 85% of the shares of Shenzhen Zhongkang Medical Engineering Co., Ltd., with building decoration and decoration professional contracting grade qualification, electronic and intelligent engineering professional contracting grade qualification, building mechanical and electrical installation engineering professional contracting qualification, purification engineering professional construction qualification, etc., with the ability to undertake P3 laboratory engineering projects in addition, Haier Bio, Yihua Health and other listed companies have also said in the interactive platform, can undertake clean laboratory-related business or have the ability to undertake P3 laboratory engineering projects.